Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NCT03457948 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Neoplasm in the Liver
Neuroendocrine Neoplasm

Interventions

PROCEDURE: Arterial Embolization
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
DEVICE: Yttrium-90 Microsphere Radioembolization

Sponsor

Nicholas Fidelman, MD

Collaborators

[object Object]
[object Object]